Clal Biotechnology Industries Ltd - Asset Resilience Ratio
Clal Biotechnology Industries Ltd (CBI) has an Asset Resilience Ratio of 1.56% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Clal Biotechnology Industries Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Clal Biotechnology Industries Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Clal Biotechnology Industries Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Clal Biotechnology Industries Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Clal Biotechnology Industries Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA1.06 Million | 1.56% |
| Total Liquid Assets | ILA1.06 Million | 1.56% |
Asset Resilience Insights
- Limited Liquidity: Clal Biotechnology Industries Ltd maintains only 1.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Clal Biotechnology Industries Ltd Industry Peers by Asset Resilience Ratio
Compare Clal Biotechnology Industries Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 72.23% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Clal Biotechnology Industries Ltd (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Clal Biotechnology Industries Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.56% | ILA1.06 Million ≈ $2.84K |
ILA67.69 Million ≈ $181.47K |
-3.25pp |
| 2023-12-31 | 4.82% | ILA7.63 Million ≈ $20.45K |
ILA158.39 Million ≈ $424.63K |
+1.84pp |
| 2022-12-31 | 2.98% | ILA5.44 Million ≈ $14.59K |
ILA182.69 Million ≈ $489.79K |
-16.29pp |
| 2020-12-31 | 19.27% | ILA118.34 Million ≈ $317.26K |
ILA614.03 Million ≈ $1.65 Million |
+6.80pp |
| 2019-12-31 | 12.48% | ILA76.98 Million ≈ $206.38K |
ILA616.97 Million ≈ $1.65 Million |
+6.24pp |
| 2018-12-31 | 6.24% | ILA63.40 Million ≈ $169.98K |
ILA1.02 Billion ≈ $2.72 Million |
+6.16pp |
| 2017-12-31 | 0.08% | ILA830.00K ≈ $2.23K |
ILA1.03 Billion ≈ $2.77 Million |
-0.40pp |
| 2016-12-31 | 0.48% | ILA5.39 Million ≈ $14.46K |
ILA1.12 Billion ≈ $3.00 Million |
-2.05pp |
| 2015-12-31 | 2.53% | ILA38.81 Million ≈ $104.04K |
ILA1.53 Billion ≈ $4.11 Million |
-10.97pp |
| 2014-12-31 | 13.51% | ILA227.94 Million ≈ $611.09K |
ILA1.69 Billion ≈ $4.52 Million |
+9.04pp |
| 2013-12-31 | 4.47% | ILA85.81 Million ≈ $230.05K |
ILA1.92 Billion ≈ $5.15 Million |
-1.25pp |
| 2012-12-31 | 5.71% | ILA99.93 Million ≈ $267.92K |
ILA1.75 Billion ≈ $4.69 Million |
-8.52pp |
| 2011-12-31 | 14.23% | ILA177.97 Million ≈ $477.12K |
ILA1.25 Billion ≈ $3.35 Million |
+5.54pp |
| 2010-12-31 | 8.69% | ILA118.56 Million ≈ $317.86K |
ILA1.36 Billion ≈ $3.66 Million |
-3.09pp |
| 2009-12-31 | 11.78% | ILA110.34 Million ≈ $295.83K |
ILA936.32 Million ≈ $2.51 Million |
+5.64pp |
| 2008-12-31 | 6.15% | ILA26.18 Million ≈ $70.17K |
ILA425.92 Million ≈ $1.14 Million |
+5.85pp |
| 2007-12-31 | 0.29% | ILA1.23 Million ≈ $3.30K |
ILA420.47 Million ≈ $1.13 Million |
-- |
About Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more